Early and locally advanced non-small-cell lung cancer: an update of the ESMO Clinical Practice Guidelines focusing on diagnosis, staging, systemic and local therapy

TY - JOUR

T1 - Early and locally advanced non-small-cell lung cancer

T2 - an update of the ESMO Clinical Practice Guidelines focusing on diagnosis, staging, systemic and local therapy

AU - ESMO Guidelines Committee

AU - Remon, J.

AU - Soria, J. C.

AU - Peters, S.

N1 - Funding Information: The ESMO Guidelines Committee acknowledges and thanks the following people who have acted as reviewers for this update: Rolf Stahel (ESMO Guidelines Steering Committee) and Marina Garassino (ESMO Faculty, metastatic NSCLC). George Pentheroudakis (Chief Medical Officer of ESMO) provided coordination and writing support. Catherine Evans, Richard Lutz and Jennifer Lamarre (ESMO staff) provided editing support. Nathan Cherny, Chair of the ESMO-MCBS Working Group, Urani Dafni ESMO-MCBS Working Group Member/Frontier Science Foundation Hellas and Giota Zygoura of Frontier Science Foundation Hellas provided review and validation of the ESMO-MCBS scores. Nicola Latino (ESMO Scientific Affairs staff) provided coordination and support of the ESMO-MCBS scores and Angela Corstorphine of Kstorfin Medical Communications Ltd. provided medical writing and editing support in the preparation of the ESMO-MCBS table; this support was funded by ESMO. Funding Information: The ESMO Guidelines Committee acknowledges and thanks the following people who have acted as reviewers for this update: Rolf Stahel (ESMO Guidelines Steering Committee) and Marina Garassino (ESMO Faculty, metastatic NSCLC). George Pentheroudakis (Chief Medical Officer of ESMO) provided coordination and writing support. Catherine Evans, Richard Lutz and Jennifer Lamarre (ESMO staff) provided editing support. Nathan Cherny, Chair of the ESMO-MCBS Working Group, Urani Dafni ESMO-MCBS Working Group Member/Frontier Science Foundation Hellas and Giota Zygoura of Frontier Science Foundation Hellas provided review and validation of the ESMO-MCBS scores. Nicola Latino (ESMO Scientific Affairs staff) provided coordination and support of the ESMO-MCBS scores and Angela Corstorphine of Kstorfin Medical Communications Ltd. provided medical writing and editing support in the preparation of the ESMO-MCBS table; this support was funded by ESMO. No external funding has been received for the preparation of these guidelines. Production costs have been covered by ESMO from central funds. JCS reports that he is on the Board of directors for Hookipa Pharma, a former full-time employee of AstraZeneca from September 2017 to December 2019 and has shares in Relay Therapeutics and Gritstone Bio. JR reports receipt of honoraria to institute for consultancy, advisory boards and/or lectures from AstraZeneca, Bristol Myers Squibb (BMS), Boehringer Ingelheim, Merck Sharp & Dohme (MSD), OSE-Immunotherapeutics, Pfizer, Roche. SP reports consultation/advisory roles for AbbVie, Amgen, AstraZeneca, Bayer, BeiGene, Biocartis, BioInvent, Blueprint Medicines, Boehringer Ingelheim, BMS, Clovis, Daiichi Sankyo, Debiopharm, Eli Lilly, Elsevier, F. Hoffmann-La Roche/Genentech, Foundation Medicine, Illumina, Incyte, IQVIA, Janssen, Medscape, MSD, Merck Serono, Merrimack, Mirati, Novartis, PharmaMar, Phosplatin Therapeutics, Pfizer, Regeneron, Sanofi, Seattle Genetics, Takeda, Vaccibody; talk in a company's organised public event: AstraZeneca, Boehringer Ingelheim, BMS, e-cancer, Eli Lilly, F. Hoffmann-La Roche/Genentech, Illumina, Medscape, MSD, Novartis, PER, Pfizer, Prime, RTP, Sanofi, Takeda; receipt of grants/research support as (sub)investigator in trials (institutional financial support for clinical trials) sponsored by Amgen, AstraZeneca, Biodesix, Boehringer Ingelheim, BMS, Clovis, F. Hoffmann-La Roche/Genentech, GlaxoSmithKline, Illumina, Lilly, MSD, Merck Serono, Mirati, Novartis, Pfizer, Phosplatin Therapeutics.

PY - 2021/12/1

Y1 - 2021/12/1

UR - http://www.scopus.com/inward/record.url?scp=85116904774&partnerID=8YFLogxK

U2 - 10.1016/j.annonc.2021.08.1994

DO - 10.1016/j.annonc.2021.08.1994

M3 - Letter

C2 - 34481037

AN - SCOPUS:85116904774

SN - 0923-7534

VL - 32

SP - 1637

EP - 1642

JO - Annals of Oncology

JF - Annals of Oncology

IS - 12

ER -